Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies.

Kinnosuke Matsumoto,Takayuki Shiroyama,Tomoki Kuge,Kotaro Miyake,Yuji Yamamoto,Midori Yoneda,Makoto Yamamoto,Yujiro Naito,Yasuhiko Suga,Kiyoharu Fukushima,Shohei Koyama,Kota Iwahori,Haruhiko Hirata,Izumi Nagatomo,Yoshito Takeda,Atsushi Kumanogoh

Translational lung cancer research（2022）

引用 1|浏览10

暂无评分

摘要

Overall, ICIs should be administered cautiously in patients with pre-existing ILD, regardless of the treatment line. Moreover, the risks of ICIP may outweigh ICI benefits, especially in second-or later-line treatment. These results need to be further confirmed by meta-analyses including more observational cohort studies in clinical setting.

查看译文

关键词

Immune checkpoint inhibitors (ICIs),non-small cell lung cancer (NSCLC),pneumonitis,pre-existing interstitial lung disease

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要